In short
Diminished ovarian reserve is a condition that affects many women trying to conceive. Getting diagnosed early means you can explore your options sooner and take action while you still have choices about your fertility journey.
Key points
- Ovarian reserve testing uses blood tests and ultrasound to estimate how many eggs remain in your ovaries, not to predict whether you'll conceive naturally
- AMH, FSH, estradiol, and antral follicle count work together to give the most complete picture of your ovarian reserve
- High FSH levels mean your body is working harder to recruit eggs, suggesting fewer eggs remain
- Women with diminished ovarian reserve can still get pregnant—you only need one good egg to conceive
- Birth control pills can temporarily lower your AMH reading, but this reverses after stopping the medication
- Testing is especially important if you're over 35, have had ovarian surgery, or underwent cancer treatment
- Clinical trials for diminished ovarian reserve typically require AMH below 0.5-1.1 ng/mL or antral follicle count below 5-7 follicles
- Egg quantity and egg quality decline in different patterns—reserve testing only measures quantity
Introduction: Who Should Consider Testing
Diminished ovarian reserve is diagnosed through ovarian reserve testing, a series of evaluations that help doctors understand how many eggs remain in your ovaries and how they might respond to fertility treatment. Not everyone needs this testing right away, but certain situations call for it sooner rather than later.
If you are 35 years or older and thinking about pregnancy, testing your ovarian reserve can give you valuable information about your reproductive timeline. Age is the strongest predictor of how many eggs you have left, and waiting too long might limit your options. Women who have tried to conceive for several months without success should also consider testing, as diminished ovarian reserve could be making conception more challenging.
You should seek diagnostic testing if you've had surgery on your ovaries, such as procedures to remove cysts or treat endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus. Medical treatments like chemotherapy or radiation can also reduce your egg supply, so if you've undergone cancer treatment, ovarian reserve testing becomes particularly important.
Women who notice changes in their menstrual cycle should pay attention. If your periods are becoming consistently shorter—for example, changing from 28-day cycles to 24 or 25-day cycles—this might signal that your ovarian reserve is declining. However, many women with diminished ovarian reserve experience no symptoms at all until they have difficulty getting pregnant, which is why testing is often the only way to know for sure.
If you have a family history of early menopause or certain genetic conditions affecting the X chromosome, such as Fragile X syndrome, you should discuss ovarian reserve testing with your healthcare provider. This genetic condition can lead to early loss of ovarian function and is responsible not only for fertility challenges but also for inherited intellectual disability and autism in some families.
Standard Diagnostic Methods
Healthcare providers use several different tests to evaluate your ovarian reserve. These tests work together to give a complete picture of how many eggs you have and how well your ovaries are functioning. Understanding what each test measures can help you make sense of your results.
Blood Tests for Hormone Levels
Blood tests form the foundation of ovarian reserve testing. Your doctor will typically measure several hormones that reflect how your ovaries are working. These tests are usually done on the second or third day of your menstrual cycle when hormone levels are at their baseline.
Anti-Müllerian hormone (AMH) is one of the most important markers for ovarian reserve. This hormone is produced by the small follicles in your ovaries—the tiny fluid-filled sacs that each contain one egg. Every small egg waiting to mature secretes a bit of AMH into your bloodstream. When you have more eggs, your AMH level is higher. When you have fewer eggs, the level drops. Unlike other hormones that change throughout your cycle, AMH stays relatively steady, so it can be measured on any day of the month. However, if you are taking birth control pills, your AMH reading might be falsely low, and stopping the pill reverses this effect.
A low AMH level, typically below 1.0 nanograms per milliliter, suggests diminished ovarian reserve. Some labs use slightly different cutoff values, with levels below 0.5 to 1.1 nanograms per milliliter indicating lower reserve. This test is especially useful when combined with other measurements to confirm the diagnosis.
Follicle-stimulating hormone (FSH) is another key hormone measured in ovarian reserve testing. FSH is produced by your brain and acts like food for your eggs, encouraging them to grow and mature. When your ovarian reserve is low and your ovaries are trying to protect the few eggs they have left, your brain has to send out more FSH to coax the eggs to develop. This means that high FSH levels actually indicate low ovarian reserve—your body is working harder to get a response from fewer eggs.
FSH levels above 10 international units per liter are considered mildly elevated. Levels above 12 to 15 international units per liter suggest significantly diminished ovarian reserve. Some fertility specialists may even cancel assisted reproduction attempts when FSH levels exceed 15, because patients with such high levels often fail to respond well to fertility medications.
Estradiol is a form of estrogen that your ovaries produce. This hormone is measured along with FSH on day three of your cycle. When estradiol levels are 80 picograms per milliliter or higher at this early point in your cycle, it suggests your ovarian reserve is declining. Elevated estradiol can sometimes mask high FSH levels, so measuring both together gives a more accurate picture of your ovarian function.
Some doctors also use a clomiphene citrate challenge test. This involves measuring your FSH and estradiol levels at the start of your cycle, then giving you medication called clomiphene citrate, and measuring the hormones again a few days later. How your body responds to this medication helps predict how your ovaries might respond to fertility treatment.
Ultrasound Examination
A transvaginal ultrasound is performed early in your menstrual cycle to count how many follicles your ovaries are offering up that month. This is called the antral follicle count (AFC). The ultrasound technician or doctor looks at both ovaries and counts all the follicles that measure between 2 and 10 millimeters in diameter. Each of these small follicles contains one egg.
Your ovaries naturally decide each month how many eggs to present as candidates for ovulation. If you have a robust egg supply, your ovaries will offer up many follicles—typically around seven or more per ovary. If your reserve is low, your ovaries protect what they have left and offer up fewer follicles, sometimes only three to five total between both ovaries. When the antral follicle count is low, pregnancy after fertility treatment becomes less likely.
The ultrasound is painless and similar to a pelvic exam. A small probe is inserted into the vagina to get a close look at the ovaries. This allows for accurate counting and measurement of the follicles. The antral follicle count is especially powerful when combined with AMH and FSH blood tests, as these different measurements confirm and support each other.
Understanding Your Test Results
No single test perfectly predicts fertility. Instead, doctors look at the combination of AMH, FSH, estradiol, and antral follicle count to understand your ovarian reserve. Age also plays an important role in interpreting these results. A woman in her late 30s with borderline test results faces different odds than a woman in her early 30s with the same numbers.
It's important to understand that ovarian reserve tests measure quantity—how many eggs you have—but they cannot measure quality. Egg quality declines with age in a different pattern than quantity. Your eggs might still be of good quality even if your reserve is lower than average, or you might have many eggs but reduced quality. This is why ovarian reserve testing cannot tell you with certainty whether you will get pregnant, only whether you might need help or should act more quickly.
Some women receive concerning test results but still conceive naturally or with minimal intervention. Others with seemingly better numbers face more challenges. The tests provide guidance about timing and treatment options but do not define your entire fertility story. Many women with diminished ovarian reserve go on to have healthy pregnancies, sometimes needing only one or two good-quality embryos achieved over multiple treatment cycles.
Diagnostic Testing for Clinical Trial Qualification
When researchers design clinical trials to study diminished ovarian reserve or test new fertility treatments, they need consistent ways to identify and classify participants. This ensures that everyone in the study truly has the condition being studied and that results can be compared across different trials. However, definitions of diminished ovarian reserve have varied widely between research studies, which has made comparing results difficult.
A review of research articles found that out of 121 studies on diminished ovarian reserve and fertility treatment, only 14 actually provided a clear definition of the condition. Even among those, eight research teams used 11 different definitions. This lack of consistency has contributed to confusing and sometimes contradictory findings about the best ways to help women with diminished ovarian reserve conceive.
Most clinical trials now use AMH levels and antral follicle count as their primary criteria for enrolling patients. These two measures have emerged as the most reliable indicators of ovarian reserve. Studies typically define diminished ovarian reserve as having an AMH level below 0.5 to 1.1 nanograms per milliliter, an antral follicle count below 5 to 7 follicles total, or both.
Some trials also include participants who have risk factors for poor ovarian response even if their test numbers are not yet severely abnormal. Risk factors might include advanced maternal age, previous poor response to fertility medications, or a history of ovarian surgery. Including these women helps researchers understand diminished ovarian reserve in its earlier stages, before the condition becomes more severe.
FSH levels are also commonly used in clinical trial enrollment criteria. Many studies require FSH levels above 10 to 12 international units per liter on day three of the cycle for participants to qualify. However, FSH can fluctuate more than AMH from cycle to cycle, which is why most modern trials prefer to use AMH or antral follicle count as their main diagnostic criteria, with FSH as a supporting measurement.
If you are considering participating in a clinical trial for diminished ovarian reserve, you will likely need to undergo all the standard diagnostic tests described earlier in this article. The trial coordinator will explain exactly which test results qualify you for the study and whether you need to repeat any tests before enrollment. Each trial has specific inclusion and exclusion criteria designed to ensure participant safety and produce meaningful scientific results.
